Navigation Links
Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study
Date:4/24/2008

s plus Copegus suggests that the 1000mg dose could deliver a rapid virologic response (RVR) rate similar to the 1500mg dose," stated Dr. Michelle Berrey, Pharmasset's Chief Medical Officer. "The confirmatory results from this additional cohort will aid us in selecting the appropriate doses to evaluate in the global Phase 2b study that is being planned to evaluate R7128 in triple combination for up to 12 weeks."

"R7128 is equally potent in vitro against HCV genotypes 1, 2, 3 and 4, and we believe it is clinically and commercially important to test R7128 in patients with these HCV genotypes," stated Schaefer Price, Pharmasset's Chief Executive Officer. "Twenty percent of U.S. HCV-infected patients and approximately 30% of European and Latin American HCV-infected patients have genotypes 2 and 3. These patients are currently treated with 24 weeks of pegylated-interferon plus ribavirin, but 20% of this population fails to achieve an SVR. By potentially addressing this unmet medical need in a patient population for whom the standard of care is only 24 weeks, we could possibly design shorter clinical trials that may provide a quicker path to the market for R7128."

Separately, the results of the 4-week Phase 1 clinical trial evaluating two oral dose levels of R7128 (500mg and 1500mg) in combination with Pegasys plus Copegus in 50 treatment-naive patients chronically infected with HCV genotype 1 will be presented at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL) in Milan, Italy on Friday, April 25, 2008 at 11:15 AM ET (US) and 5:15 PM CEST (Milan). The scientific presentation will be available for download in PDF format immediately following the EASL presentation in the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm.

Please see '/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
2. Pharmasset Receives $10 Million of Working Capital
3. Pharmasset Appoints Herbert J. Conrad as a Director
4. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
5. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
6. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
7. Pharmasset Reports Fiscal Year End 2007 Financial Results
8. Pharmasset Appoints Michael Rogers as Chief Development Officer
9. Pharmasset to Present at Three Investor Conferences in November 2007
10. Pharmasset Accesses up to $30 Million of Working Capital
11. Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014 /PRNewswire-iReach/ -- Tute ... interpretation, today announced an agreement with Lineagen, ... for Lineagen,s NextStep Dx PLUS.  Lineagen, ... and neurological disorders, currently offers FirstStep Dx ... testing service used by healthcare providers as ...
(Date:7/10/2014)... research may help in the fight against terrorism with ... quantities of explosives with the use of light and ... Sensors and Actuators B: Chemical , the researchers describe ... in concentrations as low as 6.3 ppm (parts per ... few minutes. , "Traditionally explosives detection has involved looking ...
(Date:7/10/2014)... Hall effect in bilayer graphene and shown that this ... electric field. , The fractional quantum Hall effect, ... are exposed to large magnetic fields, is a striking ... behave as a single system. However, while the basic ... of this collective behavior remain not well understood, in ...
(Date:7/10/2014)... study by researchers at the University of Illinois ... mechanisms governing the interplay of spin and heat ... of ultrafast spintronic devices for data storage and ... as well as spin-angular momentum. In a typical ... is no spin current," explained David Cahill, a ...
Breaking Biology Technology:Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Detecting trace amounts of explosives with light 2Columbia researchers observe tunable quantum behavior in bilayer graphene 2Columbia researchers observe tunable quantum behavior in bilayer graphene 3University of Illinois study advances limits for ultrafast nano-devices 2
... East/Africa and Canada -, COLLEGEVILLE, Pa., June ... WYE ), announced today the,appointment of Andreas ... effective immediately. In this new role, Mr. Krebs ... Pharmaceuticals, and Senior Vice,President, Wyeth., Mr. Krebs ...
... to take a more proactive approach ... assessment of drug safety information, HYDERABAD, India ... Services Ltd. (NYSE: SAY ), a leading ... that it has,formed an alliance with Sciformix Corporation, ...
... Md., June 26 Pinnacle Biologics, a private,full ... it has entered into a preferred stock purchase ... acquired certain,unspecified number of preferred stock shares of ... not disclosed., Pinnacle Biologics owns the marketing ...
Cached Biology Technology:Satyam Forms Partnership with Sciformix to Provide Comprehensive Drug Safety Management 2Satyam Forms Partnership with Sciformix to Provide Comprehensive Drug Safety Management 3Satyam Forms Partnership with Sciformix to Provide Comprehensive Drug Safety Management 4
(Date:7/11/2014)... for Bone and Mineral Research awarded Michael F. Holick, ... with the 2014 Louis V. Avioli Award. Holick, a ... internationally known for revolutionizing the understanding of vitamin D ... award honors a member of the American Society for ... bone and mineral basic research. It is named for ...
(Date:7/11/2014)... the National Institute of Standards and Technology (NIST) ... more effectively, they often prove that necessity is ... case recently for M. Lorna De Leoz and ... specialization of glycomics. Glycomics is the study of ... are attached to proteins and lipids and influence ...
(Date:7/11/2014)... international team of researchers, including scientists from the Max ... a reported a major step in understanding photosynthesis, the ... maintains the oxygen in its atmosphere and which is ... earth. , The researchers report the first direct ... namely the step in which a specific protein complex, ...
Breaking Biology News(10 mins):BUSM's Michael F. Holick receives American Society for Bone and Mineral Research award 2A first direct glimpse of photosynthesis in action 2
... With fewer than a dozen flowering plants out of 300,000 ... need to tap unused plants to feed the world in ... in the Comment feature of the July 4 issue of ... and rising incomes around the world, researchers estimate that food ...
... of Toronto-based researchers may be one step closer to a ... research and therapy. Induced pluripotent stem cells (iPSCs) can ... flexibly develop into many different types of cells. However, producing ... generation are largely unknown. But researchers from the University ...
... A new study published today in the journal ... the Australian, Antarctic and Indian tectonic plates, demonstrating how ... Researchers from Royal Holloway University, The Australian National ... uncertainties on how the plates evolved and where they ...
Cached Biology News:To feed the future, we must mine the wealth of the world's seed banks today 2Toronto team ID proteins key in stem cell production 2